Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent

(2017) Mohamed Wehbe et al.   International Journal of Nanomedicine

Copper diethyldithiocarbamate as an activator of Nrf2 in cultured vascular endothelial cells

(2016) Tomoya Fujie et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780

(2016) Laura H. Engelke et al.   Journal of Cancer

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development

(2016) Mohamed Wehbe et al.   PLoS One

Synergistic effect of perchlorate ions and acetonitrile medium explored for extension in copper redoximetry

(2015) M. A. Rizvi et al.   JOURNAL OF ANALYTICAL CHEMISTRY

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

(2014) Ningning Liu et al.   Scientific Reports

Advances in Copper Complexes as Anticancer Agents

(2013) Carlo Santini et al.   CHEMICAL REVIEWS

A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts

(2013) Jinbin Han et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Copper Complexes as Anticancer Agents

(2012) Cristina Marzano et al.   Anti-Cancer Agents in Medicinal Chemistry

Copper-Dependent Cytotoxicity of 8-Hydroxyquinoline Derivatives Correlates with Their Hydrophobicity and Does Not Require Caspase Activation

(2012) Saverio Tardito et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline)

(2011) Hongchao Jiang et al.   CANCER LETTERS

Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor

(2011) A. D. Schimmer   CURRENT CANCER DRUG TARGETS

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

(2011) Mantia-Smaldone et al.   Cancer Management and Research

Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry

(2010) F. Wang et al.   CURRENT MEDICINAL CHEMISTRY

Application of Metal Coordination Chemistry To Explore and Manipulate Cell Biology

(2009) Kathryn L. Haas et al.   CHEMICAL REVIEWS

Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1

(2009) D. D. Jandial et al.   CLINICAL CANCER RESEARCH

Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry

(2009) Zhen-Feng Chen et al.   DALTON TRANSACTIONS

Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells

(2009) Shumei Zhai et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity

(2009) Raul A. Barrea et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Platinum neurotoxicity pharmacogenetics

(2009) S. R. McWhinney et al.   MOLECULAR CANCER THERAPEUTICS

Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells

(2009) S. Nazeem et al.   MUTAGENESIS

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

(2009) Leonard P Rybak et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer Cells

(2008) Boris Cvek et al.   JOURNAL OF MEDICINAL CHEMISTRY